Exocyst protein subnetworks integrate Hippo and mTOR signaling to promote virus detection and cancer. Zaman A, Wu X, Lemoff A, Yadavalli S, Lee J, Wang C, Cooper J, McMillan EA, Yeaman C, Mirzaei H, White MA, Bivona TG.Cell Rep (IF: 8.109; Q1). 2021 Aug 3;36(5):109491. doi: 10.1016/j.celrep.2021.109491.PMID: 34348154
miR-200 deficiency promotes lung cancer metastasis by activating Notch signaling in cancer-associated fibroblasts. Xue B, Chuang CH, Prosser HM, Fuziwara CS, Chan C, Sahasrabudhe N, Kühn M, Wu Y, Chen J, Biton A, Chen C, Wilkinson JE, McManus MT, Bradley A, Winslow MM, Su B, He L.Genes Dev (IF: 9.527; Q1). 2021 Aug 1;35(15-16):1109-1122. doi: 10.1101/gad.347344.120. Epub 2021 Jul 22.PMID: 34301766
Kinase-mediated RAS signaling via membraneless cytoplasmic protein granules. Tulpule A, Guan J, Neel DS, Allegakoen HR, Lin YP, Brown D, Chou YT, Heslin A, Chatterjee N, Perati S, Menon S, Nguyen TA, Debnath J, Ramirez AD, Shi X, Yang B, Feng S, Makhija S, Huang B, Bivona TG.Cell (IF: 38.637; Q1). 2021 May 13;184(10):2649-2664.e18. doi: 10.1016/j.cell.2021.03.031.
CRISPR-based functional genomics in human dendritic cells. Jost M, Jacobson AN, Hussmann JA, Cirolia G, Fischbach MA, Weissman JS.Elife (IF: 7.08; Q1). 2021 Apr 27;10:e65856. doi: 10.7554/eLife.65856.PMID: 33904395
High-Throughput CRISPR Screening Identifies Genes Involved in Macrophage Viability and Inflammatory Pathways. Covarrubias S, Vollmers AC, Capili A, Boettcher M, Shulkin A, Correa MR, Halasz H, Robinson EK, O'Briain L, Vollmers C, Blau J, Katzman S, McManus MT, Carpenter S.Cell Rep (IF: 8.109; Q1). 2020 Dec 29;33(13):108541. doi: 10.1016/j.celrep.2020.108541.PMID: 33378675
Mismatch-CRISPRi Reveals the Co-varying Expression-Fitness Relationships of Essential Genes in Escherichia coli and Bacillus subtilis. Hawkins JS, Silvis MR, Koo BM, Peters JM, Osadnik H, Jost M, Hearne CC, Weissman JS, Todor H, Gross CA.Cell Syst (IF: 8.673; Q1). 2020 Nov 18;11(5):523-535.e9. doi: 10.1016/j.cels.2020.09.009. Epub 2020 Oct 19.PMID: 33080209
Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations. Negrao MV, Raymond VM, Lanman RB, Robichaux JP, He J, Nilsson MB, Ng PKS, Amador BE, Roarty EB, Nagy RJ, Banks KC, Zhu VW, Ng C, Chae YK, Clarke JM, Crawford JA, Meric-Bernstam F, Ignatius Ou SH, Gandara DR, Heymach JV, Bivona TG, McCoach CE.J Thorac Oncol (IF: 13.357; Q1). 2020 Oct;15(10):1611-1623. doi: 10.1016/j.jtho.2020.05.021. Epub 2020 Jun 13.PMID: 32540409
Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing.
Maynard A, McCoach CE, Rotow JK, Harris L, Haderk F, Kerr DL, Yu EA, Schenk EL, Tan W, Zee A, Tan M, Gui P, Lea T, Wu W, Urisman A, Jones K, Sit R, Kolli PK, Seeley E, Gesthalter Y, Le DD, Yamauchi KA, Naeger DM, Bandyopadhyay S, Shah K, Cech L, Thomas NJ, Gupta A, Gonzalez M, Do H, Tan L, Bacaltos B, Gomez-Sjoberg R, Gubens M, Jahan T, Kratz JR, Jablons D, Neff N, Doebele RC, Weissman J, Blakely CM, Darmanis S, Bivona TG.Cell (IF: 38.637; Q1). 2020 Sep 3;182(5):1232-1251.e22. doi: 10.1016/j.cell.2020.07.017. Epub 2020 Aug 20.PMID: 32822576
Combinatorial single-cell CRISPR screens by direct guide RNA capture and targeted sequencing. Replogle JM, Norman TM, Xu A, Hussmann JA, Chen J, Cogan JZ, Meer EJ, Terry JM, Riordan DP, Srinivas N, Fiddes IT, Arthur JG, Alvarado LJ, Pfeiffer KA, Mikkelsen TS, Weissman JS, Adamson B.Nat Biotechnol (IF: 36.558; Q1). 2020 Aug;38(8):954-961. doi: 10.1038/s41587-020-0470-y. Epub 2020 Mar 30.PMID: 32231336
Multi-faceted epigenetic dysregulation of gene expression promotes esophageal squamous cell carcinoma. Cao W, Lee H, Wu W, Zaman A, McCorkle S, Yan M, Chen J, Xing Q, Sinnott-Armstrong N, Xu H, Sailani MR, Tang W, Cui Y, Liu J, Guan H, Lv P, Sun X, Sun L, Han P, Lou Y, Chang J, Wang J, Gao Y, Guo J, Schenk G, Shain AH, Biddle FG, Collisson E, Snyder M, Bivona TG.Nat Commun (IF: 12.121; Q1). 2020 Jul 22;11(1):3675. doi: 10.1038/s41467-020-17227-z.PMID: 32699215
Pharmaceutical-Grade Rigosertib Is a Microtubule-Destabilizing Agent. Jost M, Chen Y, Gilbert LA, Horlbeck MA, Krenning L, Menchon G, Rai A, Cho MY, Stern JJ, Prota AE, Kampmann M, Akhmanova A, Steinmetz MO, Tanenbaum ME, Weissman JS.Mol Cell (IF: 15.584; Q1). 2020 Jul 2;79(1):191-198.e3. doi: 10.1016/j.molcel.2020.06.008.PMID: 32619469
Integration of multiple biological contexts reveals principles of synthetic lethality that affect reproducibility. Ku AA, Hu HM, Zhao X, Shah KN, Kongara S, Wu D, McCormick F, Balmain A, Bandyopadhyay S.Nat Commun (IF: 12.121; Q1). 2020 May 12;11(1):2375. doi: 10.1038/s41467-020-16078-y.PMID: 32398776
Fitness effects of CRISPR/Cas9-targeting of long noncoding RNA genes. Horlbeck MA, Liu SJ, Chang HY, Lim DA, Weissman JS.Nat Biotechnol (IF: 36.558; Q1). 2020 May;38(5):573-576. doi: 10.1038/s41587-020-0428-0. Epub 2020 Feb 24.PMID: 32094656
Betacellulin drives therapy resistance in glioblastoma. Fan Q, An Z, Wong RA, Luo X, Lu ED, Baldwin A, Mayekar MK, Haderk F, Shokat KM, Bivona TG, Weiss WA.Neuro Oncol (IF: 10.247; Q1). 2020 Apr 15;22(4):457-469. doi: 10.1093/neuonc/noz206.PMID: 31678994
Titrating gene expression using libraries of systematically attenuated CRISPR guide RNAs. Jost M, Santos DA, Saunders RA, Horlbeck MA, Hawkins JS, Scaria SM, Norman TM, Hussmann JA, Liem CR, Gross CA, Weissman JS.Nat Biotechnol (IF: 36.558; Q1). 2020 Mar;38(3):355-364. doi: 10.1038/s41587-019-0387-5. Epub 2020 Jan 13.PMID: 31932729
Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer. Rotow JK, Gui P, Wu W, Raymond VM, Lanman RB, Kaye FJ, Peled N, Fece de la Cruz F, Nadres B, Corcoran RB, Yeh I, Bastian BC, Starostik P, Newsom K, Olivas VR, Wolff AM, Fraser JS, Collisson EA, McCoach CE, Camidge DR, Pacheco J, Bazhenova L, Li T, Bivona TG, Blakely CM.Clin Cancer Res (IF: 10.107; Q1). 2020 Jan 15;26(2):439-449. doi: 10.1158/1078-0432.CCR-19-1667. Epub 2019 Sep 23.PMID: 31548343
Synthetic Essentiality of Metabolic Regulator PDHK1 in PTEN-Deficient Cells and Cancers. Chatterjee N, Pazarentzos E, Mayekar MK, Gui P, Allegakoen DV, Hrustanovic G, Olivas V, Lin L, Verschueren E, Johnson JR, Hofree M, Yan JJ, Newton BW, Dollen JV, Earnshaw CH, Flanagan J, Chan E, Asthana S, Ideker T, Wu W, Suzuki J, Barad BA, Kirichok Y, Fraser JS, Weiss WA, Krogan NJ, Tulpule A, Sabnis AJ, Bivona TG.Cell Rep (IF: 8.109; Q1). 2019 Aug 27;28(9):2317-2330.e8. doi: 10.1016/j.celrep.2019.07.063.PMID: 31461649
Exploring genetic interaction manifolds constructed from rich single-cell phenotypes. Norman TM, Horlbeck MA, Replogle JM, Ge AY, Xu A, Jost M, Gilbert LA, Weissman JS.Science (IF: 41.845; Q1). 2019 Aug 23;365(6455):786-793. doi: 10.1126/science.aax4438. Epub 2019 Aug 8.PMID: 31395745
CIC-DUX4 oncoprotein drives sarcoma metastasis and tumorigenesis via distinct regulatory programs. Okimoto RA, Wu W, Nanjo S, Olivas V, Lin YK, Ponce RK, Oyama R, Kondo T, Bivona TG.J Clin Invest (IF: 11.864; Q1). 2019 Jul 22;129(8):3401-3406. doi: 10.1172/JCI126366. eCollection 2019 Jul 22.PMID: 31329165
Engineering Multidimensional Evolutionary Forces to Combat Cancer. McCoach CE, Bivona TG.Cancer Discov (IF: 29.497; Q1). 2019 May;9(5):587-604. doi: 10.1158/2159-8290.CD-18-1196. Epub 2019 Apr 16.PMID: 30992280
High-Complexity shRNA Libraries and PI3 Kinase Inhibition in Cancer: High-Fidelity Synthetic Lethality Predictions. Mues M, Karra L, Romero-Moya D, Wandler A, Hangauer MJ, Ksionda O, Thus Y, Lindenbergh M, Shannon K, McManus MT, Roose JP.Cell Rep (IF: 8.109; Q1). 2019 Apr 9;27(2):631-647.e5. doi: 10.1016/j.celrep.2019.03.045.PMID: 30970263
Dampening oncogenic RAS signaling. Bivona TG.Science (IF: 41.845; Q1). 2019 Mar 22;363(6433):1280-1281. doi: 10.1126/science.aav6703.PMID: 30898918 No abstract available.
Cellular response to small molecules that selectively stall protein synthesis by the ribosome.Liaud N, Horlbeck MA, Gilbert LA, Gjoni K, Weissman JS, Cate JHD.PLoS Genet (IF: 5.174; Q1). 2019 Mar 15;15(3):e1008057. doi: 10.1371/journal.pgen.1008057. eCollection 2019 Mar.PMID: 30875366
Polytherapy and Targeted Cancer Drug Resistance. Chatterjee N, Bivona TG.Trends Cancer (IF: 11.093; Q1). 2019 Mar;5(3):170-182. doi: 10.1016/j.trecan.2019.02.003. Epub 2019 Feb 26.PMID: 30898264
Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology. Sabnis AJ, Bivona TG.Trends Mol Med (IF: 11.099; Q1). 2019 Mar;25(3):185-197. doi: 10.1016/j.molmed.2018.12.009. Epub 2019 Jan 24.PMID: 30686761
Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins. Neel DS, Allegakoen DV, Olivas V, Mayekar MK, Hemmati G, Chatterjee N, Blakely CM, McCoach CE, Rotow JK, Le A, Karachaliou N, Rosell R, Riess JW, Nichols R, Doebele RC, Bivona TG.Cancer Res (IF: 9.727; Q1). 2019 Feb 1;79(3):546-556. doi: 10.1158/0008-5472.CAN-18-1492. Epub 2018 Dec 11.PMID: 30538120
Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer. Shah KN, Bhatt R, Rotow J, Rohrberg J, Olivas V, Wang VE, Hemmati G, Martins MM, Maynard A, Kuhn J, Galeas J, Donnella HJ, Kaushik S, Ku A, Dumont S, Krings G, Haringsma HJ, Robillard L, Simmons AD, Harding TC, McCormick F, Goga A, Blakely CM, Bivona TG, Bandyopadhyay S.Nat Med (IF: 36.13; Q1). 2019 Jan;25(1):111-118. doi: 10.1038/s41591-018-0264-7. Epub 2018 Nov 26.PMID: 30478424
Integration of Tumor Genomic Data with Cell Lines Using Multi-dimensional Network Modules Improves Cancer Pharmacogenomics. Webber JT, Kaushik S, Bandyopadhyay S.Cell Syst (IF: 8.673; Q1). 2018 Nov 28;7(5):526-536.e6. doi: 10.1016/j.cels.2018.10.001. Epub 2018 Nov 7.PMID: 30414925
Circulating tumor DNA analysis in patients with EGFR mutant lung cancer. Nanjo S, Bivona TG.J Thorac Dis (IF: 2.046; Q2). 2018 Nov;10(Suppl 33):S4061-S4064. doi: 10.21037/jtd.2018.09.106.PMID: 30631555
RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers. Nichols RJ, Haderk F, Stahlhut C, Schulze CJ, Hemmati G, Wildes D, Tzitzilonis C, Mordec K, Marquez A, Romero J, Hsieh T, Zaman A, Olivas V, McCoach C, Blakely CM, Wang Z, Kiss G, Koltun ES, Gill AL, Singh M, Goldsmith MA, Smith JAM, Bivona TG.Nat Cell Biol (IF: 20.042; Q1). 2018 Sep;20(9):1064-1073. doi: 10.1038/s41556-018-0169-1. Epub 2018 Aug 13.PMID: 30104724
A high-throughput screen of real-time ATP levels in individual cells reveals mechanisms of energy failure. Mendelsohn BA, Bennett NK, Darch MA, Yu K, Nguyen MK, Pucciarelli D, Nelson M, Horlbeck MA, Gilbert LA, Hyun W, Kampmann M, Nakamura JL, Nakamura K.PLoS Biol (IF: 7.076; Q1). 2018 Aug 27;16(8):e2004624. doi: 10.1371/journal.pbio.2004624. eCollection 2018 Aug.PMID: 30148842
Mapping the Genetic Landscape of Human Cells. Horlbeck MA, Xu A, Wang M, Bennett NK, Park CY, Bogdanoff D, Adamson B, Chow ED, Kampmann M, Peterson TR, Nakamura K, Fischbach MA, Weissman JS, Gilbert LA.Cell (IF: 38.637; Q1). 2018 Aug 9;174(4):953-967.e22. doi: 10.1016/j.cell.2018.06.010. Epub 2018 Jul 19.PMID: 30033366
Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancer. Donnella HJ, Webber JT, Levin RS, Camarda R, Momcilovic O, Bayani N, Shah KN, Korkola JE, Shokat KM, Goga A, Gordan JD, Bandyopadhyay S.Nat Chem Biol (IF: 12.587; Q1). 2018 Aug;14(8):768-777. doi: 10.1038/s41589-018-0081-9. Epub 2018 Jun 25.PMID: 29942081
Combinatorial genetics in liver repopulation and carcinogenesis with a in vivo CRISPR activation platform. Wangensteen KJ, Wang YJ, Dou Z, Wang AW, Mosleh-Shirazi E, Horlbeck MA, Gilbert LA, Weissman JS, Berger SL, Kaestner KH.Hepatology (IF: 14.679; Q1). 2018 Aug;68(2):663-676. doi: 10.1002/hep.29626. Epub 2018 May 14.PMID: 29091290
Promoter of lncRNA Gene PVT1 Is a Tumor-Suppressor DNA Boundary Element. Cho SW, Xu J, Sun R, Mumbach MR, Carter AC, Chen YG, Yost KE, Kim J, He J, Nevins SA, Chin SF, Caldas C, Liu SJ, Horlbeck MA, Lim DA, Weissman JS, Curtis C, Chang HY.Cell (IF: 38.637; Q1). 2018 May 31;173(6):1398-1412.e22. doi: 10.1016/j.cell.2018.03.068. Epub 2018 May 3.PMID: 29731168
A Quantitative Chemotherapy Genetic Interaction Map Reveals Factors Associated with PARP Inhibitor Resistance. Hu HM, Zhao X, Kaushik S, Robillard L, Barthelet A, Lin KK, Shah KN, Simmons AD, Raponi M, Harding TC, Bandyopadhyay S.Cell Rep (IF: 8.109; Q1). 2018 Apr 17;23(3):918-929. doi: 10.1016/j.celrep.2018.03.093.PMID: 29669295
CRISPR Approaches to Small Molecule Target Identification. Jost M, Weissman JS.ACS Chem Biol (IF: 4.434; Q1). 2018 Feb 16;13(2):366-375. doi: 10.1021/acschembio.7b00965. Epub 2018 Jan 25.PMID: 29261286
A Single-Chain Photoswitchable CRISPR-Cas9 Architecture for Light-Inducible Gene Editing and Transcription. Zhou XX, Zou X, Chung HK, Gao Y, Liu Y, Qi LS, Lin MZ.ACS Chem Biol (IF: 4.434; Q1). 2018 Feb 16;13(2):443-448. doi: 10.1021/acschembio.7b00603. Epub 2017 Sep 29.PMID: 28938067
Dual gene activation and knockout screen reveals directional dependencies in genetic networks. Boettcher M, Tian R, Blau JA, Markegard E, Wagner RT, Wu D, Mo X, Biton A, Zaitlen N, Fu H, McCormick F, Kampmann M, McManus MT.Nat Biotechnol (IF: 36.558; Q1). 2018 Feb;36(2):170-178. doi: 10.1038/nbt.4062. Epub 2018 Jan 15.PMID: 29334369
Targeting RAS-driven human cancer cells with antibodies to upregulated and essential cell-surface proteins. Martinko AJ, Truillet C, Julien O, Diaz JE, Horlbeck MA, Whiteley G, Blonder J, Weissman JS, Bandyopadhyay S, Evans MJ, Wells JA.Elife (IF: 7.08; Q1). 2018 Jan 23;7:e31098. doi: 10.7554/eLife.31098.PMID: 29359686
Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Blakely CM, Watkins TBK, Wu W, Gini B, Chabon JJ, McCoach CE, McGranahan N, Wilson GA, Birkbak NJ, Olivas VR, Rotow J, Maynard A, Wang V, Gubens MA, Banks KC, Lanman RB, Caulin AF, St John J, Cordero AR, Giannikopoulos P, Simmons AD, Mack PC, Gandara DR, Husain H, Doebele RC, Riess JW, Diehn M, Swanton C, Bivona TG.Nat Genet (IF: 27.603; Q1). 2017 Dec;49(12):1693-1704. doi: 10.1038/ng.3990. Epub 2017 Nov 6.PMID: 29106415
Inducible and multiplex gene regulation using CRISPR-Cpf1-based transcription factors. Tak YE, Kleinstiver BP, Nuñez JK, Hsu JY, Horng JE, Gong J, Weissman JS, Joung JK.Nat Methods (IF: 30.822; Q1). 2017 Dec;14(12):1163-1166. doi: 10.1038/nmeth.4483. Epub 2017 Oct 30.PMID: 29083402
Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Hangauer MJ, Viswanathan VS, Ryan MJ, Bole D, Eaton JK, Matov A, Galeas J, Dhruv HD, Berens ME, Schreiber SL, McCormick F, McManus MT.Nature (IF: 42.778; Q1). 2017 Nov 9;551(7679):247-250. doi: 10.1038/nature24297. Epub 2017 Nov 1.PMID: 29088702
Combined CRISPRi/a-Based Chemical Genetic Screens Reveal that Rigosertib Is a Microtubule-Destabilizing Agent. Jost M, Chen Y, Gilbert LA, Horlbeck MA, Krenning L, Menchon G, Rai A, Cho MY, Stern JJ, Prota AE, Kampmann M, Akhmanova A, Steinmetz MO, Tanenbaum ME, Weissman JS.Mol Cell (IF: 15.584; Q1). 2017 Oct 5;68(1):210-223.e6. doi: 10.1016/j.molcel.2017.09.012.PMID: 28985505
CRISPRi-based genome-scale identification of functional long noncoding RNA loci in human cells. Liu SJ, Horlbeck MA, Cho SW, Birk HS, Malatesta M, He D, Attenello FJ, Villalta JE, Cho MY, Chen Y, Mandegar MA, Olvera MP, Gilbert LA, Conklin BR, Chang HY, Weissman JS, Lim DA.Science (IF: 41.845; Q1). 2017 Jan 6;355(6320):aah7111. doi: 10.1126/science.aah7111. Epub 2016 Dec 15.PMID: 27980086
A Multiplexed Single-Cell CRISPR Screening Platform Enables Systematic Dissection of the Unfolded Protein Response. Adamson B, Norman TM, Jost M, Cho MY, Nuñez JK, Chen Y, Villalta JE, Gilbert LA, Horlbeck MA, Hein MY, Pak RA, Gray AN, Gross CA, Dixit A, Parnas O, Regev A, Weissman JS.Cell (IF: 38.637; Q1). 2016 Dec 15;167(7):1867-1882.e21. doi: 10.1016/j.cell.2016.11.048.PMID: 27984733
PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression.Horiuchi D, Camarda R, Zhou AY, Yau C, Momcilovic O, Balakrishnan S, Corella AN, Eyob H, Kessenbrock K, Lawson DA, Marsh LA, Anderton BN, Rohrberg J, Kunder R, Bazarov AV, Yaswen P, McManus MT, Rugo HS, Werb Z, Goga A.Nat Med (IF: 36.13; Q1). 2016 Nov;22(11):1321-1329. doi: 10.1038/nm.4213. Epub 2016 Oct 24.PMID: 27775705
Compact and highly active next-generation libraries for CRISPR-mediated gene repression and activation. Horlbeck MA, Gilbert LA, Villalta JE, Adamson B, Pak RA, Chen Y, Fields AP, Park CY, Corn JE, Kampmann M, Weissman JS.Elife (IF: 7.08; Q1). 2016 Sep 23;5:e19760. doi: 10.7554/eLife.19760.PMID: 27661255
Protein Sialylation Regulates a Gene Expression Signature that Promotes Breast Cancer Cell Pathogenicity. Kohnz RA, Roberts LS, DeTomaso D, Bideyan L, Yan P, Bandyopadhyay S, Goga A, Yosef N, Nomura DK.ACS Chem Biol (IF: 4.434; Q1). 2016 Aug 19;11(8):2131-9. doi: 10.1021/acschembio.6b00433. Epub 2016 Jul 22.PMID: 27380425
Transforming Big Data into Cancer-Relevant Insight: An Initial, Multi-Tier Approach to Assess Reproducibility and Relevance. Cancer Target Discovery and Development Network.Mol Cancer Res (IF: 4.63; Q1). 2016 Aug;14(8):675-82. doi: 10.1158/1541-7786.MCR-16-0090. Epub 2016 Jul 11.PMID: 27401613
Ligand-binding domains of nuclear receptors facilitate tight control of split CRISPR activity. Nguyen DP, Miyaoka Y, Gilbert LA, Mayerl SJ, Lee BH, Weissman JS, Conklin BR, Wells JA.Nat Commun (IF: 12.121; Q1). 2016 Jul 1;7:12009. doi: 10.1038/ncomms12009.PMID: 27363581
Drug Resistance to EGFR Inhibitors in Lung Cancer. Tetsu O, Hangauer MJ, Phuchareon J, Eisele DW, McCormick F.Chemotherapy (IF: 1.641; Q2). 2016;61(5):223-35. doi: 10.1159/000443368. Epub 2016 Feb 25.PMID: 26910730
Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits. Acosta-Alvear D, Cho MY, Wild T, Buchholz TJ, Lerner AG, Simakova O, Hahn J, Korde N, Landgren O, Maric I, Choudhary C, Walter P, Weissman JS, Kampmann M.Elife (IF: 7.08; Q1). 2015 Sep 1;4:e08153. doi: 10.7554/eLife.08153.PMID: 26327694
Next-generation libraries for robust RNA interference-based genome-wide screens. Kampmann M, Horlbeck MA, Chen Y, Tsai JC, Bassik MC, Gilbert LA, Villalta JE, Kwon SC, Chang H, Kim VN, Weissman JS.Proc Natl Acad Sci U S A (IF: 9.412; Q1). 2015 Jun 30;112(26):E3384-91. doi: 10.1073/pnas.1508821112. Epub 2015 Jun 15.PMID: 26080438
Choosing the Right Tool for the Job: RNAi, TALEN, or CRISPR. Boettcher M, McManus MT.Mol Cell (IF: 15.584; Q1). 2015 May 21;58(4):575-85. doi: 10.1016/j.molcel.2015.04.028.PMID: 26000843
KRAS as a Therapeutic Target. McCormick F.Clin Cancer Res (IF: 10.107; Q1). 2015 Apr 15;21(8):1797-801. doi: 10.1158/1078-0432.CCR-14-2662.PMID: 25878360
Linking tumor mutations to drug responses via a quantitative chemical-genetic interaction map. Martins MM, Zhou AY, Corella A, Horiuchi D, Yau C, Rakhshandehroo T, Gordan JD, Levin RS, Johnson J, Jascur J, Shales M, Sorrentino A, Cheah J, Clemons PA, Shamji AF, Schreiber SL, Krogan NJ, Shokat KM, McCormick F, Goga A, Bandyopadhyay S.Cancer Discov (IF: 29.497; Q1). 2015 Feb;5(2):154-67. doi: 10.1158/2159-8290.CD-14-0552. Epub 2014 Dec 12.PMID: 25501949
A protein-tagging system for signal amplification in gene expression and fluorescence imaging. Tanenbaum ME, Gilbert LA, Qi LS, Weissman JS, Vale RD.Cell (IF: 38.637; Q1). 2014 Oct 23;159(3):635-46. doi: 10.1016/j.cell.2014.09.039. Epub 2014 Oct 9.PMID: 25307933
Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation. Gilbert LA, Horlbeck MA, Adamson B, Villalta JE, Chen Y, Whitehead EH, Guimaraes C, Panning B, Ploegh HL, Bassik MC, Qi LS, Kampmann M, Weissman JS.Cell (IF: 38.637; Q1). 2014 Oct 23;159(3):647-61. doi: 10.1016/j.cell.2014.09.029. Epub 2014 Oct 9.PMID: 25307932
Development of siRNA payloads to target KRAS-mutant cancer. Yuan TL, Fellmann C, Lee CS, Ritchie CD, Thapar V, Lee LC, Hsu DJ, Grace D, Carver JO, Zuber J, Luo J, McCormick F, Lowe SW.Cancer Discov (IF: 29.497; Q1). 2014 Oct;4(10):1182-1197. doi: 10.1158/2159-8290.CD-13-0900. Epub 2014 Aug 6.PMID: 25100204
Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors. Sos ML, Levin RS, Gordan JD, Oses-Prieto JA, Webber JT, Salt M, Hann B, Burlingame AL, McCormick F, Bandyopadhyay S, Shokat KM.Cell Rep (IF: 8.109; Q1). 2014 Aug 21;8(4):1037-48. doi: 10.1016/j.celrep.2014.07.010. Epub 2014 Aug 7.PMID: 25127139
Functional genomics platform for pooled screening and generation of mammalian genetic interaction maps. Kampmann M, Bassik MC, Weissman JS.Nat Protoc (IF: 10.419; Q1). 2014 Aug;9(8):1825-47. doi: 10.1038/nprot.2014.103. Epub 2014 Jul 3.PMID: 24992097
Systematic identification of barriers to human iPSC generation. Qin H, Diaz A, Blouin L, Lebbink RJ, Patena W, Tanbun P, LeProust EM, McManus MT, Song JS, Ramalho-Santos M.Cell (IF: 38.637; Q1). 2014 Jul 17;158(2):449-461. doi: 10.1016/j.cell.2014.05.040.PMID: 25036638
A high-coverage shRNA screen identifies TMEM129 as an E3 ligase involved in ER-associated protein degradation. van de Weijer ML, Bassik MC, Luteijn RD, Voorburg CM, Lohuis MA, Kremmer E, Hoeben RC, LeProust EM, Chen S, Hoelen H, Ressing ME, Patena W, Weissman JS, McManus MT, Wiertz EJ, Lebbink RJ.Nat Commun (IF: 12.121; Q1). 2014 May 8;5:3832. doi: 10.1038/ncomms4832.PMID: 24807418
Dynamic imaging of genomic loci in living human cells by an optimized CRISPR/Cas system. Chen B, Gilbert LA, Cimini BA, Schnitzbauer J, Zhang W, Li GW, Park J, Blackburn EH, Weissman JS, Qi LS, Huang B.Cell (IF: 38.637; Q1). 2013 Dec 19;155(7):1479-91. doi: 10.1016/j.cell.2013.12.001.PMID: 24360272
Next-generation NAMPT inhibitors identified by sequential high-throughput phenotypic chemical and functional genomic screens. Matheny CJ, Wei MC, Bassik MC, Donnelly AJ, Kampmann M, Iwasaki M, Piloto O, Solow-Cordero DE, Bouley DM, Rau R, Brown P, McManus MT, Weissman JS, Cleary ML.Chem Biol (Report missing IFs). 2013 Nov 21;20(11):1352-63. doi: 10.1016/j.chembiol.2013.09.014. Epub 2013 Oct 31.PMID: 24183972
CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Gilbert LA, Larson MH, Morsut L, Liu Z, Brar GA, Torres SE, Stern-Ginossar N, Brandman O, Whitehead EH, Doudna JA, Lim WA, Weissman JS, Qi LS.Cell (IF: 38.637; Q1). 2013 Jul 18;154(2):442-51. doi: 10.1016/j.cell.2013.06.044. Epub 2013 Jul 11.PMID: 23849981
Integrated platform for genome-wide screening and construction of high-density genetic interaction maps in mammalian cells. Kampmann M, Bassik MC, Weissman JS.Proc Natl Acad Sci U S A (IF: 9.412; Q1). 2013 Jun 18;110(25):E2317-26. doi: 10.1073/pnas.1307002110. Epub 2013 Jun 5.PMID: 23739767
Pervasive transcription of the human genome produces thousands of previously unidentified long intergenic noncoding RNAs. Hangauer MJ, Vaughn IW, McManus MT.PLoS Genet (IF: 5.174; Q1). 2013 Jun;9(6):e1003569. doi: 10.1371/journal.pgen.1003569. Epub 2013 Jun 20.PMID: 23818866
Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP, Lim WA.Cell (IF: 38.637; Q1). 2013 Feb 28;152(5):1173-83. doi: 10.1016/j.cell.2013.02.022.PMID: 23452860
A systematic mammalian genetic interaction map reveals pathways underlying ricin susceptibility. Bassik MC, Kampmann M, Lebbink RJ, Wang S, Hein MY, Poser I, Weibezahn J, Horlbeck MA, Chen S, Mann M, Hyman AA, Leproust EM, McManus MT, Weissman JS.Cell (IF: 38.637; Q1). 2013 Feb 14;152(4):909-22. doi: 10.1016/j.cell.2013.01.030. Epub 2013 Feb 8.PMID: 23394947